# Study to Evaluate the Safety, Tolerability and Immunogenicity of Recombinant Botulinum Vaccine A/B in Healthy Adults

> **NCT00098098** · PHASE1 · COMPLETED · sponsor: **DynPort Vaccine Company LLC, A GDIT Company** · enrollment: 44 (estimated)

## Conditions studied

- RECOMBINANT BOTULINUM VACCINE A/B

## Interventions

- **BIOLOGICAL:** rBV A/B

## Key facts

- **NCT ID:** NCT00098098
- **Lead sponsor:** DynPort Vaccine Company LLC, A GDIT Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-08
- **Primary completion:** —
- **Final completion:** 2005-08
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2012-08-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00098098

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00098098, "Study to Evaluate the Safety, Tolerability and Immunogenicity of Recombinant Botulinum Vaccine A/B in Healthy Adults". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT00098098. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*